4-(6-chloro-pyrid-2-yloxy)-piperidine | 99202-32-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(6-chloro-pyrid-2-yloxy)-piperidine
• 英文别名: 2-Chloro-6-(piperidin-4-yloxy)pyridine；2-chloro-6-piperidin-4-yloxypyridine
• CAS: 99202-32-1
• 化学式: C₁₀H₁₃ClN₂O
• 分子量: 212.679
• InChiKey: KUKRKVHPRGTMKR-UHFFFAOYSA-N

物化性质

• 沸点：
  316.7±42.0 °C(Predicted)
• 密度：
  1.200±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  34.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(6-chloro-pyrid-2-yloxy)-piperidine 、 (2R,3S)-2-propyl-1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidine-3-carboxylic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 C₃₃H₃₃ClF₆N₄O₄
  参考文献：
  名称：

  Structure–activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53–hDM2 inhibitors

  摘要：

  Led by the structural information of the screening hit with mDM2 protein, a structure modification of Leu26 moiety of the novel p53-hDM2 inhibitors was conducted. A structure-activity relationship study of 4-substituted piperidines revealed compound 20t with good potencies and excellent CYP450 profiles. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.03.078

文献信息

• [EN] BICYCLIC GPR119 MODULATORS<br/>[FR] MODULATEURS DE GPR119 BICYCLIQUES
  申请人：LUPIN LTD

  公开号：WO2012069917A1

  公开（公告）日：2012-05-31

  The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods of treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR1 19 receptor by using either alone or in combinations of Formula (I).

  本发明涉及一种化合物（I）的公式，该化合物对治疗、预防和/或管理与调节GPR119受体活性相关的疾病、紊乱、综合征或病况有用。该发明还涉及制备这些化合物的方法、其药物组成物。此外，该发明还涉及利用单独或以公式（I）的组合物治疗、预防和/或管理与调节GPR119受体相关的疾病、紊乱、综合征或病况的方法。
• Metalloproteinase inhibitors
  申请人：——

  公开号：US20040147573A1

  公开（公告）日：2004-07-29

  The invention provides a metalloproteinsae inhibitor compound comprising a metal binding group having formula (I), for use in the treatment of a disease or condition mediated by one or more metalloproteinase enzymes wherein X is selected from NR1, O, S; B is C or CH, Y1 and Y2 are idenpendently selected from O, S; R1 is selected from H, alkyl, haloalkyl.

  本发明提供了一种金属蛋白酶抑制剂化合物，其包含具有式（I）的金属结合基团，用于治疗由一种或多种金属蛋白酶酶介导的疾病或病况，其中X选自NR1、O、S；B为C或CH，Y1和Y2独立地选自O、S；R1选自H、烷基、卤代烷基。
• Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound
  申请人：Ishii Takahiro

  公开号：US20100009971A1

  公开（公告）日：2010-01-14

  A novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound or its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound of the present disclosure is also useful in the treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.

  一种新型的吡啶基非芳香性含氮杂环-1-羧酸酯化合物或其药学上可接受的盐具有强效的FAAH抑制活性。此外，本公开的吡啶基非芳香性含氮杂环-1-羧酸酯化合物也可用于治疗尿频、尿失禁、过度活跃的膀胱和/或疼痛。
• Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
  申请人：Peters Dan

  公开号：US20070021404A1

  公开（公告）日：2007-01-25

  This invention relates to novel aza-ring derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

  本发明涉及新型的氮杂环衍生物，可作为单胺神经递质再摄取抑制剂。在其他方面，本发明涉及使用这些化合物的治疗方法，以及包含本发明化合物的药物组合物。
• Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative
  申请人：Ishii Takahiro

  公开号：US20080306046A1

  公开（公告）日：2008-12-11

  [Problem] To provide a compound usable for treatment of diseases associated with fatty acid amide hydrolase (FAAH), especially for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain. [Means for Solution] We have found that a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative of the present invention has an excellent effect for increasing an effective bladder capacity, an excellent effect for relieving urinary frequency and an excellent anti-allodynia effect, and is therefore usable for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.

  [问题] 提供一种可用于治疗与脂肪酸酰胺水解酶（FAAH）相关的疾病的化合物，特别是用于治疗尿频和尿失禁、过度活跃的膀胱和/或疼痛。 [解决方法] 我们发现一种新型的吡啶基非芳香性含氮杂环-1-羧酸酯衍生物及其药学上可接受的盐具有强效的FAAH抑制活性。此外，本发明的吡啶基非芳香性含氮杂环-1-羧酸酯衍生物具有优异的增加有效膀胱容量的效果，优异的缓解尿频的效果和优异的抗痛觉过敏效果，因此可用于治疗尿频和尿失禁、过度活跃的膀胱和/或疼痛。